This program was recorded before the July 2, 2024 FDA approval of donanemab for Alzheimer’s disease treatment. Donanameb is an amyloid beta-directed antibody that should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials.
PROGRAM CHAIR & FACULTY PRESENTER
Marwan Noel Sabbagh, MD, FAAN, FANA
Moreno Family Chair for Alzheimer’s Research
Vice Chairman for Research and Professor
Department of Neurology
Barrow Neurological Institute
Phoenix, AZ
PROGRAM OVERVIEW
This program aims to enable clinicians to help improve care of patients with mild cognitive/behavioral impairment and Alzheimer’s disease through (1) discussion of strategies to overcome barriers to the timely diagnosis of Alzheimer’s disease; (2) applying quantitative assessments and integrating neuroimaging and specialty referral in clinical assessment; and (3) building skills to improve multidisciplinary communication and shared decision-making with patients.
TARGET AUDIENCE
This activity is designed to meet the educational needs of healthcare providers (HCPs) involved in the diagnosis and continued care of patients with Alzheimer’s disease, including neurologists, geriatricians, psychiatrists, primary care physicians, nurses, and other multidisciplinary team members.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Implement strategies to overcome barriers to the timely diagnosis of Alzheimer’s disease, addressing stigma, applying quantitative assessments, and integrating neuroimaging as well as specialty referral in clinical assessment
- Formulate strategies to optimize multidisciplinary communication and specialty referral
- Incorporate updates in clinical data to inform the identification of AD early in the disease process
- Implement shared decision-making (SDM) approaches to facilitate diagnosis and optimize management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty Member | Disclosures |
| Marwan Noel Sabbagh MD, FAAN, FANA | Consulting Fees: Anavex, Cognito Therapeutics, Eisai, GlaxoSmithKline KeiferRx, Lilly, NeuroTherapia, Novo Nordisk, Prothena, Signant Health, Roche-Genentech, Synaptogenix Ownership Interest: Athira Pharma, Lighthouse Pharmaceuticals, NeuroReserve, NeuroTau, Seq BioMarque, uMethod Health |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Melinda Chang, NP, has nothing to disclose.
- Arpan Patel, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Nicole Longo, DO, FACOI, VP Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Laura Aibara, Program Coordinator for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 07, 2024
EXPIRATION DATE: June 07, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
